XML 44 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Equity
 12 Months Ended
Dec. 31, 2023
Equity [Abstract]  
Equity

Note 16 - Equity

 

A.Composition of share capital

 

   December 31, 2023   December 31, 2022   December 31, 2021 
       Issued and       Issued and       Issued and 
   Authorized   Outstanding(1)   Authorized   outstanding(1)   Authorized   Outstanding 
   Number of shares 
Ordinary shares of NIS 10.00 par value each   17,000,000    

12,852,585

(1)   17,000,000    

12,852,585

(1)   17,000,000    12,849,295 (1) 

 

(1)Net of 258,046 Ordinary shares held as treasury shares as of December 31, 2023, 2022 and 2021, all of which have been purchased according to share buyback programs that were authorized by the Company’s Board of Directors.

 

On October 26, 2020, the Company completed a public offering in Israel of additional Series C Debenture (see Note 12B) with an aggregate principal amount of NIS 154 million (approximately €38.5 million based on the Euro/NIS exchange rate at that time) (subject to adjustments upon customary terms and 385,000 Series 1 Options, tradable on the Tel Aviv Stock Exchange, to purchase the Company’s ordinary shares at an exercise price per share of NIS 150 (approximately €37.5 based on the Euro/NIS exchange rate at that time) (subject to adjustments upon customary terms). Of the total proceeds of the offering, an amount NIS 8,891 thousand (approximately €2,224 thousand based on the Euro/NIS exchange rate at that time) was recognized in Other long-term liabilities in connection with these options. As of December 31, 2023, the amount of the liability was €2 thousand.

 

On February 23, 2021, the Company issued new Series D Convertible Debentures in a public offering in Israel in the aggregate principal amount of NIS 62,000 thousand (approximately €16,956 thousand based on the Euro/NIS exchange rate at that time) (see Note 12B). The Series D Convertible Debentures are convertible into the Company’s ordinary shares, NIS 10.00 par value per share, at a conversion price of NIS 165 (approximately €41.6 based on the Euro/NIS exchange rate at that time), subject to adjustments upon customary terms. Of the total proceeds of the offering, an amount NIS 7,504 thousand (approximately €1,890 thousand based on the Euro/NIS exchange rate at that time) was recognized in Other long-term liabilities in connection with the convertible component. As of December 31, 2023, the amount of the liability was €82 thousand.

 

During 2022, one of the Company’s employees exercised options to purchase 3,290 ordinary shares, respectively. No options were exercised during 2023.

 

B.Rights attached to shares:

 

1.Voting rights at the general meeting, right to dividend and rights upon liquidation of the Company.
   
2.Commencing August 22, 2011, the Company’s ordinary shares have been listed on the NYSE American (formerly the NYSE MKT and the NYSE Amex). On October 27, 2013, the Company’s ordinary shares were also listed for trading on the Tel Aviv Stock Exchange in Israel.

 

C.Translation reserve from foreign operation

 

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

 

D.Capital management in the Company

 

The Company’s capital management objectives are:

 

1.To preserve the Company’s ability to ensure business continuity thereby creating a return for the shareholders, investors and other interested parties.

 

2.To ensure adequate return for the shareholders by making reasonable investment decisions based on the level of internal rate of return that is in line with the Company’s business activity.

 

3.To maintain healthy capital ratios in order to support business activity and maximize shareholders value.